CTOs on the Move

LifeMine Therapeutics

www.lifeminetx.com

 
For thousands of years, people have discovered medicines from fungi by brewery. This approach has led to transformative medicines that saved millions of lives and have altered the course of medical history. Drug discovery by brewery proved to be difficult and time-consuming, leaving the field in search of a disruptive technological solution. Our genomically-enabled drug discovery engine is precisely that solution, dramatically accelerating the search for nature’s breakthrough drugs. At LifeMine, genomicists, bioinformaticians and microbiologists identify new evolutionary solutions for disease intervention; natural products chemists access the natural molecules that inspire our drug discovery efforts; biologist and chemist drug hunters craft these ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.lifeminetx.com
  • 100 Acorn Park Drive 6th Floor
    Cambridge, MA USA 02140
  • Phone: 617.945.9510

Executives

Name Title Contact Details

Funding

LifeMine Therapeutics raised $55M on 09/18/2017
LifeMine Therapeutics raised $50M on 01/07/2021

Similar Companies

G1 Therapeutics

G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company`s pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted therapies. G1 is also advancing G1T48, a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer.

Carolus Therapeutics

Carolus Therapeutics is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inform Genomics

Inform Genomics, Inc, is a privately held company that utilizes a proprietary technology platform to discover and develop genomic-based, precision medicine products that are designed to predict, with a high degree of accuracy, clinically important outcomes that assist physicians and their patients in making individualized medical decisions. Its lead development program is in oncology supportive care, with two major products currently in development--OnPART™ and HSCT/Mucositis™--designed not only to predict a patient's risk for developing common chemotherapy-related side effects, but also to assess a patient's willingness to tolerate those side effects. The Company's novel, IP-protected technology platform capitalizes on big data storage/memory and sophisticated cloud computing technologies. It consists of proprietary Bayesian networks and other advanced bioinformatic analytics combined with validated patient assessment tools. The Company's analytics discover interactions of genes and single nucleotide polymorphisms (SNPs) that can predict clinical outcomes. Inform Genomics' goal is to be a trusted partner to health care practitioners so that they, together with their patients, can make optimal health care choices based on an individual patient's needs and values.

Velicept Therapeutics

Velicept Therapeutics, Inc. is a privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs.

Xenobiotic Labs Inc

Xenobiotic Labs Inc is a Plainsboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.